Pharming Group to report first quarter 2025 financial results on May 8
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) has announced it will release its preliminary unaudited first quarter 2025 financial results on Thursday, May 8, 2025. The results will cover the period ended March 31, 2025.
The company will host an analyst and investor presentation at 13:30 CEST/07:30 EDT on the same day. Questions will only be taken from dial-in attendees who register in advance through the provided conference call link.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) ha annunciato che pubblicherà i suoi risultati finanziari preliminari non revisionati del primo trimestre 2025 giovedì 8 maggio 2025. I risultati riguarderanno il periodo terminato il 31 marzo 2025.
La società terrà una presentazione per analisti e investitori alle 13:30 CEST/07:30 EDT dello stesso giorno. Le domande saranno accettate solo dai partecipanti in chiamata che si registreranno in anticipo tramite il link fornito per la conference call.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) ha anunciado que publicará sus resultados financieros preliminares no auditados del primer trimestre de 2025 el jueves 8 de mayo de 2025. Los resultados cubrirán el período finalizado el 31 de marzo de 2025.
La compañía realizará una presentación para analistas e inversores a las 13:30 CEST/07:30 EDT el mismo día. Las preguntas solo se aceptarán de los asistentes por llamada que se registren previamente a través del enlace proporcionado para la conferencia telefónica.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR)는 2025년 1분기 잠정 감사 전 재무 결과를 2025년 5월 8일 목요일에 발표할 예정입니다. 해당 결과는 2025년 3월 31일로 종료된 기간을 포함합니다.
회사는 같은 날 13:30 CEST/07:30 EDT에 애널리스트 및 투자자 프레젠테이션을 진행합니다. 질문은 사전에 제공된 컨퍼런스 콜 링크를 통해 등록한 전화 참가자에게만 허용됩니다.
Pharming Group (Euronext : PHARM/Nasdaq : PHAR) a annoncé qu'il publiera ses résultats financiers préliminaires non audités du premier trimestre 2025 le jeudi 8 mai 2025. Ces résultats couvriront la période close au 31 mars 2025.
La société organisera une présentation pour analystes et investisseurs à 13h30 CEST/07h30 EDT le même jour. Les questions seront acceptées uniquement des participants en appel qui se seront inscrits à l'avance via le lien de la conférence téléphonique fourni.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) hat angekündigt, seine vorläufigen ungeprüften Finanzergebnisse für das erste Quartal 2025 am Donnerstag, den 8. Mai 2025 zu veröffentlichen. Die Ergebnisse umfassen den Zeitraum bis zum 31. März 2025.
Das Unternehmen wird am selben Tag um 13:30 CEST/07:30 EDT eine Präsentation für Analysten und Investoren abhalten. Fragen werden nur von Teilnehmern entgegengenommen, die sich im Voraus über den bereitgestellten Konferenzanruf-Link registrieren.
- None.
- None.
Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period ended March 31, on Thursday, May 8, 2025.
Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2025.
To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.
Conference call registration:
Please note, the Company will only take questions from dial-in attendees.
https://register-conf.media-server.com/register/BI1059030b794549a5a265dac1ee0542eb
To watch the live webcast, please register in advance using the link below.
Webcast registration:
https://edge.media-server.com/mmc/p/y45rvzpj
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
When will Pharming Group (PHARM) release Q1 2025 earnings?
What time is Pharming Group's (PHARM) Q1 2025 earnings call?
How can investors participate in Pharming Group's Q1 2025 earnings call?
Will Pharming Group (PHARM) take questions during the Q1 2025 earnings call?
